Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.

GlaxoSmithKline Intellectual Property (No. 2) Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services. The firm was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. The company was established in 2002 following an initiative of the German Federal Ministry of Education and Research to promote the German market by funding vaccine development. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs from academic research and brought them into clinical phase I and II trials.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS. Redx Pharma has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.

Cisen Pharmaceutical Ltd. engages in the manufacturing of comprehensive chemical and pharmaceutical products. It sells liver, antitumor & auxiliary, nutrition, cardiovascular, antibiotics, sedation anesthesia snooze, digestive system, cough & asthma class, immunomodulator, basic infusion, therapeutic infusion, polypropylene ampoules disease drugs. The company key products include Dirithromycin Enteric-coated Capsules, Voglibose Capsules, Cycloclenbuterol Hydrochloride Tablets, Pantoprazole Sodium Enteric-Coated Tablets, Dexmedetomidine Hydrochloride, Sodium Chloride, Iohexol, Oxaliplatin & Mannitol Injection, Adefovir Dipivoxil Tablets, Glycerol Fructose & Sodium Chloride Injection and other related drugs. Cisen Pharmaceutical was founded on November 6, 1998 and is headquartered in Jining, China.

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

ProteinLogic Ltd. is a British private company located in Cambridge. The firm develops technology platform for diagnosis of tuberculosis.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Shanghai Jiatan Pharmaceutical Technology Co., Ltd., established on 2016-11-18, Business scope includes technology development in the field of medical science and technology,Technical Services,technology transfer,technical consulting,Packaging Materials,one type,Class II medical device,Laboratory equipment and consumables,Biological reagents for non-clinical diagnosis,Edible produce,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),cosmetic,Instrumentation,Research and development of electronic products,Sales,drug development,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications.

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

MicroProbe develops, manufactures and supports wafer-test probe card products. They help semiconductor manufacturers bring new generations of non-memory devices to market faster and more economically. They include microprocessors, graphic processors, mobile RF and SoCs, and analog and mixed-signal products – imperative drivers of today’s sophisticated, multi-functional consumer mobile devices.

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

Science & Technology Corp. provides scientific, technical, and engineering services. The firm Specializes in defense chemical and biological research, test and evaluation, range support services, earth and space sciences, polar technologies, aerospace engineering and information systems engineering and support. The company was founded in 1979 and is headquartered in Hampton, VA.

FASgen, Inc. develops novel molecule therapeutics. It provides therapeutic applications for cancer, infectious diseases, and metabolic disorders including obesity and diabetes. The company was founded by James D. Dick, Frank P. Kuhajda, Albert H. Owens, and Craig A. Townsend in 2000 and is headquartered in Baltimore, MD.